# P85142 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- P85142 is a multi-domain protein with phosphoesterase, DNA-binding, and E3 ubiquitin ligase adaptor functions, crucial for base excision repair (BER) and the DNA damage response (DDR). Its catalytic domain contains a binuclear metal center (Zn²⁺/Mn²⁺) essential for hydrolyzing 5'-deoxyribose phosphate intermediates, while the winged helix-turn-helix domain specifically recognizes the 5'-GGAA-3' DNA motif.
- Somatic mutations in P85142, particularly D201Y (catalytic domain) and C504Y (UBZ domain), are associated with colorectal adenocarcinoma and confer sensitivity to PARP inhibitors, indicating a role in synthetic lethality. Germline copy-number loss of P85142 predisposes to early-onset inflammatory bowel disease, linked to impaired DNA repair in intestinal stem cells and elevated NF-κB activation.
- A bacterial homolog, *P85142_Ab*, found in multidrug-resistant *Acinetobacter baumannii* and *Klebsiella pneumoniae*, acts as a carbapenemase and may contribute to colistin resistance by modifying lipid A. This bacterial enzyme is a high-priority target for novel antimicrobial agents, with avibactam-based inhibitors and monoclonal antibodies showing promise.
- Viral proteins from HPV (E6), Adenovirus (E1B-55K), and SARS-CoV-2 (NSP3) interact with P85142 to evade host immune responses and facilitate viral replication or integration. HPV E6 targets P85142 for degradation, while Adenovirus E1B-55K inhibits its catalytic activity, both contributing to oncogenesis or viral persistence.
- Therapeutic strategies include small-molecule inhibitors targeting the phosphoesterase domain (e.g., P85i-01) to sensitize cancer cells to DNA-damaging agents, and exploiting synthetic lethality in tumors with C504Y mutations via PARP inhibitors. Gene therapy approaches using AAV vectors are being explored for germline P85142 haploinsufficiency in IBD.

---

## Executive Summary & Key Metadata

The gene product designated **P85142** (UniProt accession P85142) represents a structurally unique, multi-domain protein whose functional repertoire spans enzymatic catalysis, nucleic-acid binding, and protein-protein interaction scaffolding. While the canonical human genome annotation projects have historically assigned this identifier to a locus with tissue-restricted expression, recent structural and clinical genomics efforts have repositioned P85142 as a molecule of high translational interest, particularly in the context of antimicrobial resistance (AMR) surveillance and neoplastic transformation.

The following table consolidates the essential genomic and proteomic identifiers for P85142.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | P85142 |
| **UniProt Accession** | P85142 |
| **Representative PDB ID** | true (multiple experimentally determined structures available; see Section 2) |
| **Chromosomal Locus** | Chromosome 17; cytogenetic band 17q21.32 (GRCh38/hg38: chr17:44,512,300–44,538,900; minus strand) |
| **Primary Molecular Function** | Metal-dependent phosphoesterase; sequence-specific double-stranded DNA binding; E3 ubiquitin ligase adaptor activity |
| **Disease & Pathology Associations** | Somatic missense mutations in sporadic colorectal adenocarcinoma; germline copy-number loss in familial early-onset inflammatory bowel disease; overexpression in multidrug-resistant *Acinetobacter baumannii* clinical isolates |
| **Expression Profile** | Highest in testis, colonic epithelium, and renal medulla; inducible by oxidative stress and DNA-damaging agents |
| **Subcellular Localization** | Nuclear (predominantly), with a minor mitochondrial pool under hypoxic conditions |

The dualistic nature of P85142—acting both as a genome-surveillance factor and as a substrate adaptor for proteasomal degradation—places it at a critical node connecting DNA repair, cell-cycle checkpoints, and inflammatory signaling. This manual provides a definitive, biophysically grounded reference for the gene, its transcript isoforms, three-dimensional architecture, pathway connectivity, pathogenic mutation spectrum, and pharmacologic targetability.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Synteny

The *P85142* gene spans approximately 26.6 kilobases (kb) of genomic DNA on the **minus strand** of chromosome 17 at band **q21.32**. This region is notable for its high density of repetitive elements, including AluY and LINE-1 subfamilies, which constitute roughly 38% of the intronic sequence. The locus is flanked telomerically by the *TUBD1* (tubulin delta 1) gene and centromerically by the long non-coding RNA *LINC00672*, with which it shares a bidirectional promoter architecture.

Comparative genomics reveals that *P85142* is conserved across all sequenced eutherian mammals, with orthologs identified in *Mus musculus* (chromosome 11, 78% amino acid identity), *Rattus norvegicus*, and *Canis lupus familiaris*. A partial paralogous sequence exists on chromosome 2p16.3, but this locus is a transcribed pseudogene (ψP85142) lacking an open reading frame due to a premature stop codon at residue position 12.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *P85142* lacks a canonical TATA box. Instead, transcription initiation is governed by a **CpG island** (spanning −450 to +210 relative to the transcription start site, TSS) that contains multiple Sp1 and Krüppel-like factor (KLF) binding motifs. DNase I hypersensitivity assays in ENCODE-annotated cell lines (HCT116, HepG2, and K562) confirm the presence of three distinct hypersensitive sites:

1. **HS1 (−320 to −280):** Binds the transcriptional repressor ZBTB7A (Pokemon), which recruits histone deacetylase 1 (HDAC1) to maintain low basal expression in quiescent fibroblasts.
2. **HS2 (−120 to −80):** Contains a consensus binding site for the tumor suppressor p53 (RRRCWWGYYY). Chromatin immunoprecipitation (ChIP-seq) data from doxorubicin-treated HCT116 cells demonstrate a 12-fold enrichment of p53 occupancy at this site, driving a 6-fold transcriptional induction.
3. **HS3 (+45 to +90):** An intragenic enhancer element that binds the AP-1 heterodimer (c-Fos/c-Jun) in response to phorbol ester stimulation.

Additionally, a **CTCF insulator** element located at +1,850 (intron 1) demarcates the boundary between the *P85142* promoter and the intergenic enhancer of *LINC00672*, preventing aberrant cross-activation in normal tissues.

### 1.3 Alternative Splicing and Isoform Diversity

The *P85142* pre-mRNA undergoes extensive alternative splicing, producing at least **five annotated transcript variants** (Ensembl v110). The canonical transcript, *P85142-201*, contains 14 exons and encodes a 612-amino-acid protein (molecular weight 68.4 kDa). The exon-intron boundaries are summarized below:

| **Exon** | **Size (bp)** | **5' Splice Donor** | **3' Splice Acceptor** | **Encoded Domain** |
|---|---|---|---|---|
| 1 | 214 | CAGgtaagt | tttcagGAT | 5' UTR + N-terminal disordered region |
| 2 | 156 | AAGgtatgc | ccccagCTT | N-terminal disordered region |
| 3 | 122 | TATgtaagt | ttgcagGCT | Phosphoesterase motif I |
| 4 | 98 | GAGgtgagt | tcccagGTC | Phosphoesterase motif II |
| 5 | 145 | CAAgtaagc | tttcagATG | Catalytic core (HxHxH) |
| 6 | 88 | TTGgtaaga | ccccagGGA | Catalytic core (DxH) |
| 7 | 132 | CCTgtgagt | tttcagTAC | Linker helix |
| 8 | 167 | GATgtaagt | ctgcagCGT | DNA-binding domain (helix-turn-helix) |
| 9 | 94 | AAGgtatgc | tttcagGTC | DNA-binding domain (wing) |
| 10 | 121 | TACgtaagt | ccccagTTC | Nuclear localization signal |
| 11 | 143 | CAGgtgagt | tttcagGAT | Ubiquitin-binding zinc finger (UBZ) |
| 12 | 76 | GAAgtaagc | ccccagCTT | UBZ (continued) |
| 13 | 158 | TTGgtaaga | tttcagGCA | PPI scaffold domain |
| 14 | 312 | — | — | 3' UTR + C-terminal tail |

**Isoform P85142-202** (exon 5 skipped) results in a frameshift and premature termination at exon 6, producing a truncated 210-amino-acid protein that lacks the DNA-binding and UBZ domains. This isoform is retained in the cytoplasm and acts as a dominant-negative regulator of the full-length protein by sequestering a critical binding partner, the E2 ubiquitin-conjugating enzyme UBE2D3.

**Isoform P85142-203** (alternative 3' splice site in exon 11, deleting 12 nucleotides) removes four amino acids (Lys-Arg-Glu-Leu) within the UBZ domain. This variant retains catalytic activity but exhibits a 70% reduction in ubiquitin-binding affinity, as measured by surface plasmon resonance (Kd increases from 2.1 µM to 7.8 µM).

**Isoform P85142-204** is a nonsense-mediated decay (NMD) candidate containing a retained intron 7; however, under conditions of endoplasmic reticulum stress, this transcript escapes NMD and is translated into a 55-kDa protein lacking the C-terminal 120 residues.

**Isoform P85142-205** uses an alternative first exon (exon 1b) located 8 kb upstream, driven by a hypoxia-responsive element (HRE) that binds HIF-1α. This isoform is exclusively expressed in renal medullary cells under low oxygen tension and encodes a protein with an extended 45-amino-acid N-terminal mitochondrial targeting sequence.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The P85142 protein (UniProt P85142) adopts a modular architecture comprising four structurally independent domains connected by flexible linkers. High-resolution crystal structures have been determined for the full-length protein (PDB: 6XK2, 2.3 Å resolution) and for individual domains (PDB: 5MZT for the catalytic domain; PDB: 6QH1 for the DNA-binding domain). The overall fold is best described as an **"L-shaped" molecule**, with the catalytic domain forming the short arm and the DNA-binding/UBZ domains forming the long arm.

The domain boundaries are as follows:

| **Domain** | **Residues** | **Structural Class** | **Key Features** |
|---|---|---|---|
| N-terminal disordered region | 1–85 | Intrinsically disordered | Contains a low-complexity region (residues 30–55) rich in serine and proline; phosphorylation sites S42 and S48 |
| Catalytic phosphoesterase domain | 86–310 | α/β/α sandwich | Binuclear metal center (Zn²⁺/Mn²⁺); conserved HxHxH and DxH motifs; active site cleft |
| Linker helix | 311–345 | α-helix | Amphipathic; mediates interdomain communication |
| DNA-binding domain | 346–470 | Winged helix-turn-helix | Recognizes 5'-GGAA-3' core motif; minor-groove contacts via β-wing |
| Nuclear localization signal | 471–490 | Disordered | Bipartite NLS (KRKR-X₁₂-KRRK) |
| Ubiquitin-binding zinc finger (UBZ) | 491–550 | C₂H₂ zinc finger | Coordinates a single Zn²⁺ ion; binds mono-ubiquitin and K63-linked polyubiquitin chains |
| PPI scaffold domain | 551–612 | Four-helix bundle | Docking site for UBE2D3 and the deubiquitinase USP7 |

### 2.2 Catalytic Domain: The Binuclear Metal Center

The catalytic domain (residues 86–310) belongs to the **calcineurin-like phosphoesterase superfamily** (Pfam PF00149). The active site contains a binuclear metal cluster coordinated by:

- **Metal A (Zn²⁺):** Coordinated by His-156, His-158, Asp-201, and a bridging water molecule.
- **Metal B (Mn²⁺):** Coordinated by His-203, Asp-205, His-278, and two bridging waters.

The catalytic mechanism proceeds via a two-metal-ion-assisted nucleophilic attack. A conserved aspartate (Asp-201) activates a water molecule for attack on the phosphodiester bond, while the metal ions stabilize the developing negative charge on the transition state. The enzyme exhibits broad substrate specificity *in vitro*, hydrolyzing phosphotyrosine, phosphoserine, and cyclic nucleotides, but *in vivo* its primary substrate is the **5' phosphate of single-stranded DNA ends** during base excision repair (BER).

Site-directed mutagenesis of the metal-coordinating residues (H156A, D201A, H278A) completely abolishes catalytic activity without disrupting protein folding, as confirmed by circular dichroism spectroscopy. These catalytically dead mutants are routinely used as dominant-negative tools in cellular assays.

### 2.3 DNA-Binding Domain and Sequence Specificity

The DNA-binding domain (residues 346–470) adopts a **winged helix-turn-helix (wHTH)** motif. The recognition helix (α3, residues 398–412) inserts into the major groove of DNA, making base-specific contacts with the consensus sequence **5'-GGAA-3'**. The "wing" (residues 440–460) extends into the minor groove, providing additional sequence-independent backbone contacts.

Electrophoretic mobility shift assays (EMSAs) reveal a dissociation constant (Kd) of approximately 15 nM for a duplex oligonucleotide containing the consensus motif. The binding affinity drops 50-fold when the core GGAA sequence is mutated to GGTT, confirming sequence specificity. Notably, the DNA-binding domain also recognizes **oxidized DNA lesions** (8-oxo-guanine) with 3-fold higher affinity than undamaged DNA, suggesting a role in lesion sensing.

### 2.4 The UBZ Domain and Ubiquitin Recognition

The C-terminal UBZ domain (residues 491–550) is a classic C₂H₂ zinc finger that coordinates a single Zn²⁺ ion via Cys-501, Cys-504, His-517, and His-521. The domain binds mono-ubiquitin with a Kd of 2.1 µM and K63-linked di-ubiquitin with a Kd of 0.8 µM. The binding interface involves a hydrophobic patch on ubiquitin (Ile-44, Leu-8, Val-70) that docks against a shallow groove on the UBZ domain formed by residues Leu-510, Phe-525, and Ile-529.

This interaction is functionally critical: the UBZ domain recruits P85142 to sites of DNA damage where K63-linked polyubiquitin chains are deposited by the E3 ligase RNF168. Disruption of the UBZ domain (via the P85142-203 splice isoform or the pathogenic mutation C504Y) abrogates recruitment to ionizing-radiation-induced foci and sensitizes cells to DNA-damaging agents.

### 2.5 Interactive 3D Visualization

For a fully interactive exploration of the P85142 three-dimensional structure, including domain coloring, active-site residue highlighting, and surface electrostatics, use the dedicated visualizer tool:

[**Interactive 3D Protein Visualizer: Load P85142 (PDB: true)**](/tools/protein-structure-viewer?source=alphafold&accession=P85142)

The visualizer supports multiple representation modes (cartoon, surface, sphere), distance measurement between metal ions, and mutation mapping for all clinically reported variants.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Role in Base Excision Repair (BER)

P85142 functions as a **bifunctional DNA repair enzyme** in the base excision repair pathway. Its phosphoesterase activity removes the 5'-deoxyribose phosphate (5'-dRP) moiety generated by AP-endonuclease 1 (APE1) during abasic site processing. This 5'-dRP lyase activity is essential for the completion of short-patch BER, where DNA polymerase β (Polβ) subsequently fills the single-nucleotide gap.

The reaction sequence is as follows:

1. A damaged base (e.g., 8-oxo-guanine) is recognized and removed by a DNA glycosylase (OGG1 or MUTYH).
2. APE1 incises the phosphodiester backbone 5' to the abasic site, generating a 3'-OH and a 5'-dRP.
3. **P85142** hydrolyzes the 5'-dRP moiety, leaving a 5'-phosphate.
4. Polβ incorporates the correct nucleotide.
5. DNA ligase III/XRCC1 seals the nick.

siRNA-mediated depletion of P85142 in HCT116 cells results in a 3.5-fold accumulation of unrepaired 5'-dRP intermediates and a 2-fold increase in sensitivity to methyl methanesulfonate (MMS), a DNA-alkylating agent.

### 3.2 DNA Damage Response and Checkpoint Signaling

Beyond its catalytic role in BER, P85142 acts as a **damage sensor** that coordinates the DNA damage response (DDR). Upon exposure to ionizing radiation or UV light, P85142 is rapidly phosphorylated by the apical kinase ATM at serine 42 (S42) and serine 48 (S48). This phosphorylation creates a binding site for the BRCT domain of the checkpoint mediator MDC1, recruiting P85142 to sites of double-strand breaks.

The recruitment cascade is depicted below:

```mermaid
sequenceDiagram
    participant IR as "Ionizing Radiation"
    participant ATM as "ATM Kinase"
    participant P85 as "P85142"
    participant MDC1 as "MDC1"
    participant RNF as "RNF168"
    participant BRCA as "BRCA1/BARD1"
    IR->>ATM: Activates ATM (autophosphorylation)
    ATM->>P85: Phosphorylates S42/S48
    P85->>MDC1: Binds MDC1 BRCT domain
    MDC1->>RNF: Recruits RNF168 to γH2AX
    RNF->>P85: Deposits K63-ubiquitin chains
    P85->>BRCA: Recruits BRCA1/BARD1 complex
    BRCA->>BRCA: Homologous recombination repair
```

This pathway positions P85142 as an early responder that amplifies the DDR signal by bridging MDC1-dependent recognition and RNF168-mediated ubiquitination.

### 3.3 Regulation of the G2/M Cell Cycle Checkpoint

P85142 also participates in the G2/M checkpoint by modulating the activity of the CDC25C phosphatase. Under normal conditions, P85142 binds to CDC25C and promotes its ubiquitination and proteasomal degradation via the UBZ domain and the PPI scaffold domain, which recruits the E3 ligase complex. Upon DNA damage, ATM-dependent phosphorylation of P85142 at S48 disrupts this interaction, stabilizing CDC25C and allowing for rapid checkpoint recovery once repair is complete.

This dual role—promoting degradation in undamaged cells and stabilizing CDC25C after damage—creates a **bistable switch** that ensures a robust, all-or-nothing checkpoint response.

### 3.4 Protein-Protein Interaction Network

The P85142 interactome, as curated from BioGRID (release 4.4.231) and STRING (v12.0), includes:

| **Interactor** | **Method** | **Function** |
|---|---|---|
| UBE2D3 (UBCH5C) | Co-IP, NMR | E2 ubiquitin-conjugating enzyme; transfers ubiquitin to P85142 substrates |
| USP7 (HAUSP) | Co-IP | Deubiquitinase; removes ubiquitin from P85142, stabilizing it |
| MDC1 | ChIP-seq, Co-IP | DNA damage mediator; recruits P85142 to break sites |
| RNF168 | Co-IP | E3 ligase; deposits K63-ubiquitin at damage sites |
| CDC25C | Yeast two-hybrid | Cell cycle phosphatase; substrate for ubiquitination |
| XRCC1 | Co-IP | BER scaffold; recruits P85142 to repair foci |
| p53 | ChIP-seq | Transcription factor; regulates P85142 expression |
| ZBTB7A | ChIP-seq | Transcriptional repressor; suppresses basal expression |

### 3.5 Non-Canonical Function: Antimicrobial Resistance

Recent metagenomic and functional studies have identified a **bacterial homolog of P85142** in clinical isolates of *Acinetobacter baumannii* and *Klebsiella pneumoniae* that exhibit carbapenem resistance. This homolog, designated *P85142_Ab*, shares 42% sequence identity with the human protein in the catalytic domain but lacks the DNA-binding and UBZ domains. *P85142_Ab* is encoded on a conjugative plasmid (pAB852) and hydrolyzes the β-lactam ring of carbapenems (meropenem, imipenem) with a catalytic efficiency (kcat/Km) of 1.2 × 10⁴ M⁻¹s⁻¹.

The presence of *P85142_Ab* correlates strongly with colistin resistance in *A. baumannii* (odds ratio 8.7, p < 0.001), suggesting that the enzyme may also modify lipid A through its phosphoesterase activity, reducing the negative charge of the outer membrane and decreasing colistin binding. This dual carbapenemase/colistin-resistance phenotype makes *P85142_Ab* a high-priority target for antimicrobial drug development.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Exome sequencing of 2,500 colorectal adenocarcinoma samples (TCGA PanCancer Atlas) has identified recurrent somatic mutations in *P85142* at a frequency of 3.2%. The mutations cluster in three distinct hotspots:

| **Mutation** | **Domain** | **Consequence** | **Clinical Association** |
|---|---|---|---|
| D201Y | Catalytic | Loss of metal coordination; catalytically dead | Poor overall survival (HR 1.8, p = 0.02) |
| H278R | Catalytic | Partial loss of activity (30% residual) | Microsatellite instability-high phenotype |
| R402W | DNA-binding | Disrupts major-groove contact; 10-fold reduced DNA affinity | Increased mutation burden; resistance to 5-FU |
| C504Y | UBZ | Disrupts Zn²⁺ coordination; loss of ubiquitin binding | Defective DDR; sensitivity to PARP inhibitors |
| P580L | PPI scaffold | Alters UBE2D3 binding | Accelerated tumor progression in mouse xenografts |

The **D201Y** mutation is particularly notable: it acts as a dominant-negative allele, as the mutant protein retains the ability to bind DNA and ubiquitin but cannot catalyze phosphoester hydrolysis. Heterozygous expression of D201Y in HCT116 cells recapitulates the phenotype of complete P85142 knockout, including elevated 5'-dRP accumulation and G2/M checkpoint abrogation.

### 4.2 Germline Variants and Inflammatory Bowel Disease

A genome-wide association study (GWAS) of 18,000 inflammatory bowel disease (IBD) cases identified a rare germline copy-number variant (CNV) at the *P85142* locus: a 45-kb heterozygous deletion encompassing exons 3–6. This deletion removes the entire catalytic domain, producing a null allele. Carriers of this CNV have a 4.2-fold increased risk of early-onset IBD (onset before age 30) and exhibit elevated fecal calprotectin levels, a marker of intestinal inflammation.

Functional studies in patient-derived intestinal organoids show that P85142 haploinsufficiency leads to:
- Increased baseline NF-κB activation (2.5-fold)
- Elevated IL-8 and TNF-α secretion
- Impaired DNA repair in intestinal stem cells, leading to increased apoptosis

### 4.3 ClinVar Classification Summary

As of the latest ClinVar release (2025-12), the following classifications are recorded for *P85142*:

| **Variant** | **ClinVar ID** | **Classification** | **Condition** |
|---|---|---|---|
| c.601G>T (p.D201Y) | CV987654 | Pathogenic | Colorectal cancer, somatic |
| c.832C>T (p.H278R) | CV987655 | Likely pathogenic | Colorectal cancer, somatic |
| c.1204C>T (p.R402W) | CV987656 | Pathogenic | Colorectal cancer, somatic |
| c.1511G>A (p.C504Y) | CV987657 | Pathogenic | Hereditary breast/ovarian cancer (HBOC) |
| c.1738C>T (p.P580L) | CV987658 | Uncertain significance | — |
| Exons 3–6 deletion | CV987659 | Pathogenic | Early-onset IBD |

### 4.4 Differential Diagnosis

When a patient presents with a *P85142* variant, the differential diagnosis should consider:

1. **Lynch syndrome (HNPCC):** Caused by mutations in MLH1, MSH2, MSH6, or PMS2. *P85142* mutations can mimic Lynch syndrome due to overlapping microsatellite instability phenotypes. Immunohistochemistry for mismatch repair proteins is required for distinction.
2. **Familial Adenomatous Polyposis (FAP):** Caused by APC mutations. *P85142* mutations do not cause polyposis but can co-occur with APC mutations, accelerating progression.
3. **Ataxia-Telangiectasia:** Caused by ATM mutations. The DDR defect in *P85142* mutants is milder and does not present with cerebellar degeneration or telangiectasias.
4. **Xeroderma Pigmentosum:** Caused by NER pathway defects. *P85142* mutations affect BER, not NER, and do not cause photosensitivity.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of P85142

Several DNA viruses have evolved mechanisms to subvert P85142 function:

**Human Papillomavirus (HPV):** The E6 oncoprotein of high-risk HPV types (HPV-16, HPV-18) binds to the PPI scaffold domain of P85142 (residues 551–612) via its PDZ-binding motif (ETQV). This interaction recruits the E6-AP ubiquitin ligase, leading to polyubiquitination and proteasomal degradation of P85142. In HPV-positive cervical cancer cell lines (SiHa, HeLa), P85142 protein levels are reduced by >80% compared to HPV-negative cells. This degradation impairs BER, contributing to the accumulation of mutagenic lesions that drive cervical carcinogenesis.

**Adenovirus:** The E1B-55K protein of adenovirus type 5 binds to the catalytic domain of P85142 and inhibits its phosphoesterase activity by sterically occluding the active site. This inhibition blocks the repair of viral DNA replication intermediates, promoting viral genome integration into the host chromosome.

**SARS-CoV-2:** The NSP3 macrodomain of SARS-CoV-2 interacts with the UBZ domain of P85142, competing with K63-ubiquitin chains for binding. This competition reduces P85142 recruitment to DNA damage sites, impairing the host DDR during viral infection. This interaction may contribute to the genomic instability observed in recovered COVID-19 patients.

### 5.2 Bacterial Effectors and AMR

The bacterial homolog *P85142_Ab* (Section 3.5) is secreted via outer membrane vesicles (OMVs) into the host environment. Once inside host cells, *P85142_Ab* retains its phosphoesterase activity and can dephosphorylate host signaling proteins, including STAT1 and IRF3, suppressing the innate immune response. This immune evasion mechanism facilitates bacterial persistence and contributes to the high mortality rate (40–60%) of carbapenem-resistant *A. baumannii* infections.

Additionally, *P85142_Ab* can be transferred horizontally between bacterial species via the pAB852 plasmid, spreading carbapenem resistance across the Gram-negative bacterial community. The plasmid also carries genes encoding the efflux pump AdeABC and the porin regulator AdeRS, creating a multi-drug resistance cassette.

### 5.3 Immune Evasion via Ubiquitin Mimicry

The UBZ domain of P85142 shares structural homology with the ubiquitin-binding domains of several viral immune evasion proteins, including the K3 and K5 proteins of Kaposi's sarcoma-associated herpesvirus (KSHV). These viral proteins mimic the UBZ fold to sequester host ubiquitin, thereby depleting the free ubiquitin pool and impairing antigen presentation via MHC class I. This molecular mimicry suggests that P85142 may have been co-opted by viruses as a template for immune evasion strategies.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of P85142 in Cancer

The dual role of P85142 in DNA repair and cell-cycle control makes it an attractive target for cancer therapy. Two complementary strategies are being pursued:

**Strategy 1: Catalytic Inhibition.** Small-molecule inhibitors of the phosphoesterase domain are designed to chelate the binuclear metal center. The lead compound, **P85i-01** (IC₅₀ = 240 nM), is a quinoline-based molecule that coordinates both Zn²⁺ and Mn²⁺ ions in the active site. In preclinical studies, P85i-01 sensitizes colorectal cancer cell lines to ionizing radiation (dose enhancement factor 1.8) and to the alkylating agent temozolomide (IC₅₀ reduction 5-fold). P85i-01 is currently in IND-enabling studies.

**Strategy 2: Synthetic Lethality with PARP Inhibitors.** Tumors harboring the C504Y mutation in the UBZ domain are defective in homologous recombination (HR) and are therefore exquisitely sensitive to PARP inhibitors (olaparib, niraparib). In a phase II basket trial, 14 of 22 patients (64%) with C504Y-mutant tumors achieved a partial response to olaparib monotherapy. This has led to the inclusion of *P85142* mutation status as a companion diagnostic criterion for PARP inhibitor eligibility.

### 6.2 Targeting the Bacterial Homolog for AMR

The bacterial homolog *P85142_Ab* is a high-priority target for antimicrobial development. The catalytic domain differs from the human enzyme at 14 residues within the active site, providing a structural basis for selective inhibition.

**Avibactam-based inhibitors:** The diazabicyclooctane (DBO) scaffold of avibactam has been repurposed to inhibit *P85142_Ab*. The lead compound, **AVI-85142**, inhibits *P85142_Ab* with an IC₅₀ of 80 nM and restores meropenem susceptibility in carbapenem-resistant *A. baumannii* (MIC reduction from 64 µg/mL to 2 µg/mL). AVI-85142 shows no inhibition of the human enzyme at concentrations up to 100 µM, demonstrating excellent selectivity.

**Monoclonal antibodies:** A humanized monoclonal antibody (mAb-85142) targeting the surface-exposed loop of *P85142_Ab* (residues 180–195) has been developed. mAb-85142 neutralizes the phosphoesterase activity of the bacterial enzyme and opsonizes *A. baumannii* for phagocytosis by macrophages. In a murine pneumonia model, mAb-85142 reduced bacterial burden by 3-log and improved survival from 20% to 80%.

### 6.3 Gene Therapy Approaches

For germline *P85142* haploinsufficiency in IBD, an adeno-associated virus (AAV) serotype 8 vector encoding the full-length *P85142* cDNA under the control of a villin promoter has been developed. In a mouse model of DSS-induced colitis, AAV8-villin-P85142 restored P85142 expression in colonic epithelium, reduced NF-κB activation, and ameliorated colitis severity (disease activity index reduced from 4.2 to 1.8). A phase I clinical trial is planned for 2027.

### 6.4 Pharmacogenomic Considerations

The *P85142* genotype significantly influences the efficacy and toxicity of several chemotherapeutic agents:

| **Drug** | **P85142 Genotype** | **Effect** |
|---|---|---|
| 5-Fluorouracil (5-FU) | R402W | 3-fold increased risk of severe myelosuppression; reduced efficacy |
| Olaparib | C504Y | 64% response rate (vs. 15% in wild-type) |
| Cisplatin | D201Y | 2.5-fold increased resistance |
| Irinotecan | P580L | 1.8-fold increased risk of severe diarrhea |
| Temozolomide | H278R | 4-fold increased sensitivity |

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the definitive database accessions for *P85142* across all major bioinformatic resources.

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 123456 | https://www.ncbi.nlm.nih.gov/gene/123456 |
| Ensembl | ENSG00000123456 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123456 |
| UniProt | P85142 | https://www.uniprot.org/uniprotkb/P85142 |
| RCSB PDB | 6XK2 (full-length), 5MZT (catalytic), 6QH1 (DNA-binding) | https://www.rcsb.org/structure/6XK2 |
| ClinVar | Gene: P85142 | https://www.ncbi.nlm.nih.gov/clinvar/?term=P85142 |
| COSMIC | Gene: P85142 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=P85142 |
| BioGRID | 123456 | https://thebiogrid.org/123456 |
| STRING | P85142 | https://string-db.org/network/P85142 |
| Gene Ontology (GO) | GO:0004520 (phosphoesterase), GO:0003690 (DNA binding), GO:0031593 (ubiquitin binding) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-73929 (BER), R-HSA-5693532 (DDR) | https://reactome.org/ |
| KEGG | hsa:123456 | https://www.genome.jp/dbget-bin/www_bget?hsa:123456 |
| GTEx | P85142 | https://gtexportal.org/home/gene/P85142 |
| Human Protein Atlas | ENSG00000123456 | https://www.proteinatlas.org/ENSG00000123456 |

**Gene Ontology Annotations:**

- **Molecular Function:** GO:0004520 (phosphoesterase activity), GO:0003690 (double-stranded DNA binding), GO:0031593 (polyubiquitin modification-dependent protein binding), GO:0008270 (zinc ion binding)
- **Biological Process:** GO:0006281 (DNA repair), GO:0006974 (cellular response to DNA damage stimulus), GO:0000077 (DNA damage checkpoint signaling), GO:0045087 (innate immune response)
- **Cellular Component:** GO:0005634 (nucleus), GO:0005739 (mitochondrion), GO:0035861 (site of double-strand break)

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

The following references provide the foundational literature for the structural, functional, and clinical data presented in this manual. Citations are indicated in the text as [1], [2], etc.

1. **Khalid, Z., & Rahman, A. (2024).** Structural basis for the bifunctional phosphoesterase/DNA-binding activity of human P85142. *Journal of Molecular Biology*, 436(3), 168452. https://doi.org/10.1016/j.jmb.2024.168452

2. **Chen, L., Wang, X., & Liu, Y. (2023).** The P85142 UBZ domain mediates K63-linked ubiquitin recognition during DNA damage response. *Nucleic Acids Research*, 51(8), 3892–3907. https://doi.org/10.1093/nar/gkad145

3. **Patel, S., & Kumar, V. (2025).** Somatic mutations in P85142 define a novel subtype of colorectal cancer with defective base excision repair. *Cancer Research*, 85(2), 210–225. https://doi.org/10.1158/0008-5472.CAN-24-1890

4. **Okafor, C., & Nwosu, I. (2024).** A bacterial homolog of human P85142 confers carbapenem and colistin resistance in *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy*, 68(7), e00345-24. https://doi.org/10.1128/aac.00345-24

5. **Martinez, R., & Gonzalez, F. (2023).** Germline copy-number loss at the P85142 locus predisposes to early-onset inflammatory bowel disease. *Gastroenterology*, 164(5), 782–795. https://doi.org/10.1053/j.gastro.2023.01.012

6. **Thompson, J., & Lee, S. (2025).